Peter Marks (physician)
Peter Marks | |
|---|---|
| Born | November 5, 1963 Brooklyn, New York, U.S. |
| Education | Columbia University (BS) New York University (MD, PhD) |
| Occupation | Business executive |
| Employer | Eli Lilly (2025–present) |
| Known for | FDA Director of the Center for Biologics Evaluation and Research |
| Title | Head of infectious disease and senior vice president of molecule discovery |
| Scientific career | |
| Fields | Hematology, Oncology |
| Institutions | Brigham and Women's Hospital Yale University |
| Doctoral advisor | Frederick R. Maxfield |
Peter Marks is an American hematologist and oncologist who currently serves as the head of infectious disease and senior vice president of molecule discovery at Eli Lilly. He previously served as the director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, having been appointed to the position in 2016 after previously serving as deputy director. Among other duties, Marks oversaw the FDA vaccine program. In March 2025, Marks resigned from his position.